BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 29549850)

  • 1. Ketone bodies as a predictor of prognosis of hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Sasaki R; Taura N; Miyazoe Y; Yamamichi S; Nakashiki S; Yamashima M; Suehiro T; Honda T; Shibata H; Ozawa E; Miuma S; Akazawa Y; Miyaaki H; Matsumoto T; Nakao K; Ashizawa K
    Nutrition; 2018 Jun; 50():97-103. PubMed ID: 29549850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supportive treatment, resection and transcatheter arterial chemoembolization in resectable hepatocellular carcinoma: an analysis of survival in 419 patients.
    Huang YH; Wu JC; Chau GY; Lui WY; King KL; Chiang JH; Yen SH; Sheng WY; Hou MC; Lu CL; Chang FY; Lee SD
    Eur J Gastroenterol Hepatol; 1999 Mar; 11(3):315-21. PubMed ID: 10333206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABO Blood Group Differentials on Survival in Hepatocellular Carcinoma Patients Treated with Chemoembolization.
    Bannangkoon K; Hongsakul K; Sripongpun P; Kaewdech A; Chamroonkul N; Tubtawee T; Piratvisuth T
    Asian Pac J Cancer Prev; 2021 Nov; 22(11):3685-3692. PubMed ID: 34837928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative transarterial chemoembolization for hepatocellular carcinoma.
    Kishi Y; Saiura A; Yamamoto J; Koga R; Seki M; Morimura R; Yoshioka R; Kokudo N; Yamaguchi T
    Hepatogastroenterology; 2012 Oct; 59(119):2295-9. PubMed ID: 23435144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.
    Sergio A; Cristofori C; Cardin R; Pivetta G; Ragazzi R; Baldan A; Girardi L; Cillo U; Burra P; Giacomin A; Farinati F
    Am J Gastroenterol; 2008 Apr; 103(4):914-21. PubMed ID: 18177453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.
    Bettinger D; Spode R; Glaser N; Buettner N; Boettler T; Neumann-Haefelin C; Brunner TB; Gkika E; Maruschke L; Thimme R; Schultheiss M
    BMC Gastroenterol; 2017 Aug; 17(1):98. PubMed ID: 28797231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization.
    Hsu CY; Huang YH; Su CW; Lin HC; Chiang JH; Lee PC; Lee FY; Huo TI; Lee SD
    Liver Int; 2010 Jan; 30(1):77-84. PubMed ID: 19818004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
    Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
    BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study.
    Yu Y; Lang Q; Chen Z; Li B; Yu C; Zhu D; Zhai X; Ling C
    Cancer; 2009 Nov; 115(22):5132-8. PubMed ID: 19672999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.
    Hsieh MY; Lin ZY; Chuang WL
    Kaohsiung J Med Sci; 2011 Aug; 27(8):314-22. PubMed ID: 21802642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of transcatheter arterial chemoembolization after radiofrequency ablation as a combined therapy for Chinese patients with hepatocellular carcinoma.
    Xu RC; Liu HC; Li JL; Li K; Ou SY; Yu ZY; Kong Y; Ma GA; Shao WS
    Curr Med Res Opin; 2015 Aug; 31(8):1553-60. PubMed ID: 26067770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic factors and model of primary liver cancer treated with transcatheter arterial chemoembolization combined with radiofrequency ablation].
    Li J; Zhu WL; Kang XX; Zheng L; Guo CY; Yu P; Xiao JC
    Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):787-791. PubMed ID: 29061025
    [No Abstract]   [Full Text] [Related]  

  • 14. 3D conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma.
    Zou LQ; Zhang BL; Chang Q; Zhu FP; Li YY; Wei YQ; Guan YS
    World J Gastroenterol; 2014 Dec; 20(45):17227-34. PubMed ID: 25493039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial.
    Peng ZW; Zhang YJ; Chen MS; Xu L; Liang HH; Lin XJ; Guo RP; Zhang YQ; Lau WY
    J Clin Oncol; 2013 Feb; 31(4):426-32. PubMed ID: 23269991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis.
    Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Pai JT; Loong CC; Chiou YY; Lee RC; Lee FY; Huo TI; Lee SD
    Ann Surg Oncol; 2012 Mar; 19(3):842-9. PubMed ID: 21913008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional polymorphisms in the NPAS2 gene are associated with overall survival in transcatheter arterial chemoembolization-treated hepatocellular carcinoma patients.
    Yuan P; Wang S; Zhou F; Wan S; Yang Y; Huang X; Zhang Z; Zhu Y; Zhang H; Xing J
    Cancer Sci; 2014 Jul; 105(7):825-32. PubMed ID: 24754267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
    Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
    J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization.
    Prajapati HJ; Kim HS
    PLoS One; 2017; 12(2):e0170750. PubMed ID: 28170405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Epithelial Cell Adhesion Molecule-Positive Circulating Tumor Cell Count Predicts Poor Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization.
    Shen J; Wang WS; Zhu XL; Ni CF
    J Vasc Interv Radiol; 2018 Dec; 29(12):1678-1684. PubMed ID: 30392801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.